Less than half of patients received their insurer’s approval for prescriptions of the type of cholesterol-lowering drug known as PCSK9 inhibitors, according to new research in the American Heart Association’s (AHA) journal Circulation. PCSK9 inhibitors, like Repatha (evolocumab) and Praluent (alirocumab), work by increasing the removal of low-density lipoprotein (LDL) or “bad” cholesterol from the… Continue reading Insurance Approval Lagging on Costly New Cholesterol Drug